{
  "id": "5a722d9f2dc08e987e000004",
  "type": "summary",
  "question": "What is mechanism of action of Benralizumab?",
  "ideal_answer": "Benralizumab is a humanised, anti-interleukin 5 receptor \u03b1 monoclonal antibody that directly and rapidly depletes eosinophils, reduces asthma exacerbations, and improves lung function for patients with severe eosinophilic asthma.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28583618",
    "http://www.ncbi.nlm.nih.gov/pubmed/28919200",
    "http://www.ncbi.nlm.nih.gov/pubmed/27906698",
    "http://www.ncbi.nlm.nih.gov/pubmed/28737051",
    "http://www.ncbi.nlm.nih.gov/pubmed/28545978",
    "http://www.ncbi.nlm.nih.gov/pubmed/22136436",
    "http://www.ncbi.nlm.nih.gov/pubmed/28109128",
    "http://www.ncbi.nlm.nih.gov/pubmed/26205082",
    "http://www.ncbi.nlm.nih.gov/pubmed/25306557",
    "http://www.ncbi.nlm.nih.gov/pubmed/27119985",
    "http://www.ncbi.nlm.nih.gov/pubmed/27609408",
    "http://www.ncbi.nlm.nih.gov/pubmed/27859832",
    "http://www.ncbi.nlm.nih.gov/pubmed/29059618",
    "http://www.ncbi.nlm.nih.gov/pubmed/28406319",
    "http://www.ncbi.nlm.nih.gov/pubmed/27609406",
    "http://www.ncbi.nlm.nih.gov/pubmed/25208464",
    "http://www.ncbi.nlm.nih.gov/pubmed/28971769",
    "http://www.ncbi.nlm.nih.gov/pubmed/29086236",
    "http://www.ncbi.nlm.nih.gov/pubmed/27097165",
    "http://www.ncbi.nlm.nih.gov/pubmed/28530840"
  ],
  "snippets": [
    {
      "text": "Since IL-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting IL-5/IL-5R\u03b1 have been developed and/or marketed, including Mepolizumab, Reslizumab, and Benralizumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29059618",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Mepolizumab, reslizumab, and benralizumab target IL-5, a key cytokine for eosinophils.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27906698",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Benralizumab is a humanized, afucosylated, anti-interleukin-5 receptor \u03b1, immunoglobulin G (IgG)1\u03ba monoclonal antibody.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28109128",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A global meta-analysis was first conducted followed by an indirect comparison of each IL-5-targeting drug: benralizumab, reslizumab and mepolizumab. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27859832",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These include monoclonal antibodies against IL-5 or IL-5 receptor alpha (mepolizumab, reslizumab, and benralizumab), IL-13 (lebrikizumab and tralokinumab), IL-4 receptor alpha (dupilumab), IgE (omalizumab), and anti-thymic stromal lymphopoietin (tezepelumab) and small molecule therapies such as prostaglandin D2blockers (fevipiprant and timapiprant).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28583618",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "However, there is research underway investigating interleukin-based monoclonal antibodies such as benralizumab, an anti-IL-5R monoclonal antibody which is currently in phase III clinical development. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28406319",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Benralizumab is a humanised, anti-interleukin 5 receptor \u03b1 monoclonal antibody that directly and rapidly depletes eosinophils, reduces asthma exacerbations, and improves lung function for patients with severe eosinophilic asthma. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28545978",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": ". We investigated whether benralizumab, a monoclonal antibody directed against the alpha subunit of the interleukin-5 receptor that significantly reduces the incidence of asthma exacerbations, was also effective as an oral glucocorticoid-sparing therapy in patients relying on oral glucocorticoids to manage severe asthma associated with eosinophilia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28530840",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Benralizumab--a humanized mAb to IL-5R\u03b1 with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22136436",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Benralizumab is a monoclonal antibody that binds the \u03b1 subunit of the receptor to IL-5.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22136436",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We assessed the safety and efficacy of benralizumab, a monoclonal antibody against interleukin-5 receptor \u03b1 that depletes eosinophils by antibody-dependent cell-mediated cytotoxicity, for patients with severe, uncontrolled asthma with eosinophilia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27609408",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "While previous monoclonal antibodies against the IL-5 ligand resulted in inconsistent improvements in asthma outcomes, benralizumab has shown promise.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27119985",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Benralizumab is a monoclonal antibody against IL-5 receptor, and has an enhanced antibody dependent cell-mediated cytotoxicity function.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27119985",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Anti-IL-5-based therapies (mepolizumab and reslizumab are humanized monoclonal antibodies (hmAbs) that recognize free IL-5, benralizumab is a hmAb directed at the \u03b1 subunit of the IL-5R) target the IL-5-signaling in eosinophilic asthma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28737051",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Benralizumab is a humanised, afucosylated, anti-interleukin-5 receptor \u03b1 monoclonal antibody that induces direct, rapid, and nearly complete depletion of eosinophils.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28971769",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Benralizumab is a humanized anti-IL5 receptor \u03b1 (IL5R\u03b1) monoclonal antibody (mAb) with enhanced (afucosylation) antibody-dependent cell-mediated cytotoxicity (ADCC) function.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26205082",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: Benralizumab is a humanised, afucosylated, anti-interleukin-5 receptor \u03b1 monoclonal antibody that induces direct, rapid, and nearly complete depletion of eosinophils.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27609406",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Benralizumab is a monoclonal antibody that targets interleukin-5 receptor \u03b1 to deplete blood eosinophils and improve the clinical outcomes of allergic asthma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29086236",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Expert opinion: Benralizumab has the advantage over other anti-IL-5 therapies to target the IL-5R\u03b1 itself.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28737051",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Benralizumab is an anti-interleukin-5 receptor \u03b1 monoclonal antibody that depletes blood and airway eosinophils.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27097165",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Benralizumab is a monoclonal antibody that targets interleukin-5 receptor \u03b1 to deplete blood eosinophils and improve the clinical outcomes of allergic asthma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29086236",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Anti-IL-5-based therapies (mepolizumab and reslizumab are humanized monoclonal antibodies (hmAbs) that recognize free IL-5, benralizumab is a hmAb directed at the \u03b1 subunit of the IL-5R) target the IL-5-signaling in eosinophilic asthma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28737051",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND Benralizumab is an anti-eosinophilic, anti-interleukin-5 receptor \u03b1 monoclonal antibody that has been shown to significantly reduce asthma exacerbations and improve lung function for patients with severe, uncontrolled asthma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28919200",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "As IL-5 is implicated in disease states that are mediated by eosinophils, benralizumab is an attractive option for use in the management of asthma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22136436",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTRODUCTION Benralizumab is a monoclonal antibody that binds the \u03b1 subunit of the receptor to IL-5.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22136436",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Benralizumab is a humanized, afucosylated, anti-interleukin-5 receptor \u03b1, immunoglobulin G (IgG) 1 \u03ba monoclonal antibody.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28109128",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We investigated whether benralizumab, a monoclonal antibody directed against the alpha subunit of the interleukin-5 receptor that significantly reduces the incidence of asthma exacerbations, was also effective as an oral glucocorticoid-sparing therapy in patients relying on oral glucocorticoids to manage severe asthma associated with eosinophilia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28530840",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In a phase 2b dose-ranging study, we aimed to assess the efficacy and safety of benralizumab, an anti-interleukin 5 receptor \u03b1 monoclonal antibody that depletes blood and airway eosinophils, in adults with uncontrolled eosinophilic asthma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25306557",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, depletes blood and sputum eosinophils.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25208464",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}